Home > Insider Trading > Filing (0001209191-19-044975)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1649198	Kim Mceachron	301 Penobscot Dr. Redwood City CA 94063	Chief People Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-08-05	9,665	$30.69	46,137	No	4	M	Direct
Common Stock	Acquisiton	2019-08-05	2,438	$28.05	48,575	No	4	M	Direct
Common Stock	Disposition	2019-08-05	12,103	$71.53	36,472	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-08-05	9,665	$0.00	9,665	$30.69
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-08-05	2,438	$0.00	2,438	$28.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2022-03-12	No	4	M	Direct
6,562		2023-01-31	No	4	M	Direct

Footnotes

Includes an aggregate of 11,261 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 18, 2019.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $71.13 to $72.03.
The option became exercisable as to 25% of the shares on March 12, 2013, and became exercisable as to 1/48th of the shares each full month thereafter.
The option became exercisable as to 25% of the shares on January 31, 2014, and became exercisable as to 1/48th of the shares each full month thereafter.